Composition for diagnosing of colorectal cancer and pharmaceutical composition for preventing or treating colorectal cancer using CNOT11
The use of CNOT11-binding substances in diagnostic kits and inhibitors addresses the lack of effective colorectal cancer treatments by enabling accurate diagnosis and targeted therapy through CNOT11 inhibition and ferroptosis induction.
Patent Information
- Application Number
- KR1020240078100
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2024-06-17
- Publication Date
- 2026-11-06
- Estimated Expiration
- 2044-06-17
AI Technical Summary
Current treatments for colorectal cancer are limited, with no effective drug-based therapies, and there is a need for diagnostic methods, preventive compositions, and screening tools to address this challenging cancer.
A composition and kit that utilize substances binding to CNOT11 mRNA or protein, such as antibodies, aptamers, or nucleic acids, to diagnose colorectal cancer, and a pharmaceutical composition with CNOT11 inhibitors to prevent or treat the cancer by inhibiting c-Myc activity and inducing ferroptosis.
The approach enables effective diagnosis, prevention, and treatment of colorectal cancer by targeting CNOT11, providing diagnostic tools and therapeutic agents that inhibit cancer cell growth and induce cell death, thereby improving treatment outcomes.
Smart Images

Figure 112024064878890-PAT00001_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a composition for diagnosing colorectal cancer using CNOT11, a diagnostic kit, and a method for providing information for diagnosing colorectal cancer. In addition, the present invention relates to a pharmaceutical composition for preventing or treating colorectal cancer, a health functional food, and a screening method for colorectal cancer treatments. Background Technology
[0003] Colon cancer is a leading cause of cancer-related deaths in the United States; as of 2010, it is estimated that approximately 102,900 people in the U.S. would be diagnosed with the disease, and 51,370 would die. Recently, the incidence rate has been on the rise in Asia as well due to Westernized dietary habits. Major contributing factors are known to include excessive consumption of animal fats, sugars, and alcohol, as well as a lack of fiber, antioxidant vitamins, vegetables, and fruits. In particular, unlike the intake of fiber-rich foods such as vegetables and grains, consuming large amounts of animal fat and meat results in smaller stool volumes and takes a long time for the contents to pass through the colon and be excreted. Furthermore, it increases the excretion of bile acids and sterols and alters the composition of bacterial species within the colon, leading to an increase in the types of bacteria that chemically alter these substances. Consequently, a large amount of carcinogens is generated, and the prolonged presence and contact time within the colon contribute to the frequent occurrence of colon cancer. Colorectal cancer is a representative solid tumor characterized by a large number of cells growing in a clustered form around blood vessels; as such, treatment methods are extremely limited, making it one of the cancers that is difficult to cure completely. In other words, because drugs cannot properly penetrate to the center of these clustered cells, it is not an easy task to completely eliminate them. Currently, there are virtually no drug-based treatments available for colorectal cancer, and surgical therapies such as surgery or radiation therapy are the only viable options; however, it is difficult to expect a complete cure with these treatments.
[0004] Therefore, many researchers are conducting extensive studies to effectively inhibit the growth of various cancer cells, including colorectal cancer cells, by developing methods to effectively suppress the growth of colorectal cancer cells.
[0005] Apoptosis is a crucial mechanism by which anticancer drugs exert inhibitory effects on cancer cell proliferation; it is an active death that occurs through the regulation of the expression and activity of various genes and proteins in accordance with programmed signals within the cell. Since disruption of the apoptotic process induces the survival and growth of damaged or initiating cells, the inhibition of apoptosis plays a vital role in the process of carcinogenesis. Furthermore, it has been reported that substances with cancer-preventive effects induce the death of these abnormal cells, and that the induction of apoptosis by these substances is at least associated with their cancer-preventive activity.
[0006] The inventors confirmed the overexpression of CNOT11 in colon cancer cells and confirmed that CNOT11 contributes to the inhibition of cancer cell proliferation and cancer growth by inhibiting the activity of c-Myc and inducing ferroptosis, thereby completing the present invention. Prior art literature
[0008] Korean Registered Patent No. 2096498. The problem to be solved
[0009] The technical problem that the present invention aims to solve is to provide a composition and a kit for diagnosing colorectal cancer.
[0010] In addition, the technical problem that the present invention aims to solve is to provide a method for providing information for the diagnosis of colorectal cancer.
[0011] In addition, the technical problem that the present invention aims to solve is to provide a pharmaceutical composition for the prevention or treatment of colorectal cancer.
[0012] In addition, the technical problem that the present invention aims to solve is to provide a health functional food for the prevention or improvement of colorectal cancer.
[0013] In addition, the technical problem that the present invention aims to solve is to provide a screening method for colorectal cancer treatments.
[0015] The technical problems that the present invention aims to solve are not limited to those mentioned above, and other unmentioned technical problems will be clearly understood by those skilled in the art to which the present invention belongs from the description below. means of solving the problem
[0017] To achieve the above technical problem, one embodiment of the present invention provides a composition for diagnosing colorectal cancer comprising a substance that specifically binds to CNOT11 (CCR4-NOT Transcription Complex Subunit 11) mRNA or the protein thereof.
[0018] In an embodiment of the present invention, the material may be at least one selected from the group consisting of antibodies, aptamers, DNA, RNA, proteins, and polypeptides.
[0019] To achieve the above technical problem, another embodiment of the present invention provides a colorectal cancer diagnostic kit comprising the above composition.
[0020] To achieve the above technical problem, another embodiment of the present invention provides a method for providing information for diagnosing colorectal cancer, comprising the step of measuring the expression level of CNOT11 mRNA or the protein in a sample separated from a diagnostic target.
[0021] In an embodiment of the present invention, if the expression level is higher than the expression level of the control group, the diagnostic subject may further include a step of determining that the likelihood of developing colorectal cancer is higher than that of the control group.
[0022] In an embodiment of the present invention, the sample may be selected from the group consisting of tissue, cell, blood, serum, plasma, saliva, or urine.
[0023] To achieve the above technical problem, another embodiment of the present invention provides a pharmaceutical composition for the prevention or treatment of colorectal cancer comprising a CNOT11 inhibitor.
[0024] In an embodiment of the present invention, the CNOT11 inhibitor may be a nucleic acid, antibody, aptamer, peptide, protein, compound, or natural product.
[0025] In an embodiment of the present invention, the prevention or treatment may be achieved by inhibiting c-Myc activity or inducing ferroptosis.
[0026] To achieve the above technical problem, another embodiment of the present invention provides a health functional food for preventing or improving colorectal cancer comprising a CNOT11 inhibitor.
[0027] To achieve the above technical problem, another embodiment of the present invention provides a screening method for colorectal cancer treatments comprising the steps of: treating a biological sample expressing CNOT11 mRNA or its protein with a candidate substance; measuring the expression level of CNOT11 mRNA or its protein in the sample treated with the candidate substance; and selecting a candidate substance whose expression level is reduced compared to a control group not treated with the candidate substance.
[0028] In an embodiment of the present invention, the biological sample may be selected from the group consisting of tissue, cell, blood, serum, plasma, saliva, or urine. Effects of the invention
[0030] The present invention relates to a composition for diagnosing colorectal cancer, a diagnostic kit including the same, a method for providing information for diagnosing colorectal cancer, a pharmaceutical composition for preventing or treating colorectal cancer, a health functional food for preventing or improving colorectal cancer, and a screening method for colorectal cancer treatments. The composition, kit, and method of the present invention are expected to be usefully utilized for targeting and screening of therapeutic substances for the prevention and treatment of colorectal cancer by using CNOT11 as a biomarker.
[0031] The effects of the present invention are not limited to the effects described above, and should be understood to include all effects that can be inferred from the composition of the invention described in the description or claims of the present invention. Brief explanation of the drawing
[0033] Figure 1 shows the results of observing CNOT11 overexpression in colorectal cancer compared to normal colorectal cells using western blotting after extracting proteins from colon cells and colorectal cancer cell lines. Figure 2A is the colorectal cancer cell line HCT116 p53+ / + This is an experimental result confirming that the cell viability of cells treated with CNOT11 siRNA was lower compared to the control group not treated with CNOT11 siRNA, and Figure 2B shows the colorectal cancer cell line HCT116 p53+ / + The experimental results showed that the cell proliferation rate was lower in the group treated with CNOT11 siRNA compared to the control group, based on the number of colonies into which CNOT11 siRNA was introduced. Figure 3A shows CNOT11 siRNA in colorectal cancer cell line HCT116 via siRNA transfection. p53+ / +Figure 3B shows the results of comparing the expression levels of c-Myc, a representative oncogenic gene, by western blotting after protein extraction following introduction, and the results of comparing the expression levels of c-Myc by western blotting after protein extraction at different times following introduction of CNOT11 siRNA. Figure 4 shows colon cancer cell line HCT116 using CNOT11 siRNA transfection. p53+ / + This is an image showing the results of observing the location of the nucleus and the expression of c-Myc in the cell through fluorescent staining using the immunofluorescence experiment technique after introduction. Figure 5A shows the colon cancer cell line HCT116 p53+ / + Figure 5B shows the results of observing changes in the expression of representative ferroptosis-related factors GPX4, xCT / SLC7A11, and Keap1 using western blotting after introducing CNOT11 siRNA via transfection and extracting proteins, and Figure 5B shows the colorectal cancer cell line HCT116 into which CNOT11 siRNA was introduced via transfection. p53+ / + This is an image of the experimental results confirming that more ROS was generated inside the cell through DCFDA testing. Specific details for implementing the invention
[0034] The present invention will be described in detail below.
[0036] The present invention relates to a composition for diagnosing colorectal cancer.
[0037] The present invention comprises a composition that specifically binds to CNOT11 (CCR4-NOT Transcription Complex Subunit 11) mRNA or the protein thereof.
[0038] CNOT11 is one of the subunits that make up the CCR4-NOT transcription complex, which includes subunits such as CNOT1, CNOT2, CNOT3, CNOT10, and CNOT11, each of which has a different role and function. No specific use of the CNOT11 gene is known in relation to regulating the growth of colorectal cancer in colorectal cancer cells.
[0039] CNOT11 is present in the sample from which the diagnosis is made, and its mRNA or protein sequence may be a sequence known to the NCBI GenBank, etc. For example, the sequence of the individual species to which the diagnosis is made may be used.
[0040] The above diagnostic subjects are animals that currently have colorectal cancer or have a history of having colorectal cancer, or other animals for which information is sought to predict or diagnose the onset of colorectal cancer, and the said animals may be mammals, including humans.
[0041] The above sample is separated from the subject of diagnosis and may be, for example, tissue, cell, blood, serum, plasma, saliva, or urine, and specifically may be cancer tissue separated from the subject of diagnosis, but is not limited thereto.
[0042] The above material is not limited to being able to detect CNOT11 mRNA or its protein, but may be, for example, at least one selected from the group consisting of antibodies, aptamers, DNA, RNA, proteins, and polypeptides.
[0043] In this invention, "antibody" means a protein molecule specific to an antigenic site. For the purposes of this invention, an antibody means an antibody that specifically binds to the marker protein CNOT11, and may include monoclonal antibodies, polyclonal antibodies, and recombinant antibodies.
[0044] The above monoclonal antibody may be prepared using a hybridoma method or phage antibody library technology widely known in the art, but is not limited thereto.
[0045] The above-mentioned polyclonal antibody can be produced by a method widely known in the art, comprising injecting the above-mentioned protein antigen into an animal and collecting blood from the animal to obtain serum containing the antibody. Such polyclonal antibody may be produced from any animal species host, such as goats, rabbits, sheep, monkeys, horses, pigs, cattle, and dogs, but is not limited thereto.
[0046] In addition, the antibodies of the present invention may also include special antibodies such as chimeric antibodies and humanized antibodies.
[0047] The aforementioned "peptide" has the advantage of high binding affinity to target substances and does not undergo denaturation even during heat or chemical treatment. Furthermore, due to its small molecular size, it can be attached to other proteins to be used as a fusion protein. Specifically, since it can be attached to high-molecular-weight protein chains, it can be utilized as a diagnostic kit and a drug delivery material.
[0048] The term "aptamer" above refers to a type of polynucleotide composed of a special kind of single-stranded nucleic acid (DNA, RNA, or modified nucleic acid) that has a stable tertiary structure in itself and can bind to target molecules with high affinity and specificity. As described above, aptamers can specifically bind to antigenic substances just like antibodies, but because they are composed of polynucleotides that are more stable than proteins, have a simple structure, and are easy to synthesize, they can be used as a substitute for antibodies.
[0049] The substance that specifically binds to the mRNA may be a sense and antisense primer or a probe, but is not limited thereto.
[0050] In the present invention, “primer” refers to a short gene sequence that serves as a starting point for DNA synthesis, and means an oligonucleotide synthesized for the purpose of use in diagnosis, DNA sequencing, etc. The primers can typically be synthesized and used with a length of 15 to 30 base pairs, but this may vary depending on the purpose of use, and can be modified by methylation, capping, etc., using known methods.
[0051] In the present invention, "probe" refers to a nucleic acid capable of specifically binding to mRNA of several to hundreds of base pairs in length, produced through enzymatic chemical separation, purification, or synthesis processes. The presence or absence of mRNA can be confirmed by labeling with radioactive isotopes or enzymes, and the probe can be designed and modified using known methods.
[0052] Since the nucleotide sequence of the gene encoding CNOT11, the sequence complementary to the nucleotide sequence, or the probe or primer that specifically binds to the fragment of the nucleotide is known, a person skilled in the art can design the primer or probe based on the sequence according to conventional methods in the art.
[0053] The composition of the present invention is a substance to be used for predicting or diagnosing colorectal cancer in patients suspected of having colorectal cancer, and can be used to predict or diagnose colorectal cancer in suspected patients by treating a sample separated from a patient for diagnosis and measuring the expression level of CNOT11 mRNA or protein in the sample.
[0054] For example, by comparing the expression level of CNOT11 mRNA or its protein in a sample from a patient suspected of having colorectal cancer with the expression level of a normal control group, if the expression level of the patient suspected of having colorectal cancer is higher than that of the normal control group, it can be determined that the likelihood of developing colorectal cancer is higher than that of the normal control group.
[0056] The present invention relates to a colorectal cancer diagnostic kit comprising the above composition.
[0057] The above kit may not only include a substance that specifically binds to CNOT11 mRNA or its protein, but may also include one or more other component compositions, solutions, or devices suitable for an analysis method that measures the expression level of CNOT11 mRNA or its protein used by the kit.
[0058] If the above kit is intended to measure the expression level of CNOT11 mRNA or protein, it may be a kit containing essential elements required to perform RT-PCR. In addition to individual primer pairs specific to the mRNA of the marker gene, the RT-PCR kit may include test tubes or other suitable containers, reaction buffer, deoxyribonucleotides (dNTPs), enzymes such as Taq-polymerase and reverse transcriptase, DNase, RNase inhibitors, DEPC-water, sterile water, etc. Additionally, it may include primer pairs specific to the gene used as a quantitative control.
[0059] The above kit may include a substrate, a suitable buffer solution, a secondary antibody labeled with a chromogenic enzyme or fluorescent substance, and a chromogenic substrate for the immunological detection of a nucleotide sequence of a gene encoding CNOT11, a sequence complementary to the nucleotide sequence, a fragment of the nucleotide, or a substance that specifically binds to a protein encoded by the nucleotide sequence. The above substrate may be a nitrocellulose membrane, a 96-well plate synthesized from polyvinyl resin, a 96-well plate synthesized from polystyrene resin, and a glass slide glass, etc., and the chromogenic enzyme may be peroxidase or alkaline phosphatase, the fluorescent material may be FITC, RITC, etc., and the chromogenic substrate may be 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) or o-phenylenediamine (OPD), tetramethylbenzidine (TMB), etc.
[0060] The above kit may be a microarray capable of measuring the expression level of CNOT11 mRNA. The above microarray can be easily manufactured by a person skilled in the art according to a method known in the art using the above indicator factor, and according to one embodiment, it may be a microarray in which a cDNA having a sequence corresponding to the mRNA of a gene encoding the CNOT11 protein or a fragment thereof is attached to a substrate as a probe.
[0061] In addition, the kit of the present invention may include an antibody that specifically binds to a marker component, a secondary antibody conjugate conjugated with a label that develops color upon reaction with a substrate, a color-developing substrate solution that reacts with the label, a washing solution, and an enzyme reaction stopping solution, and may be manufactured in multiple separate packages or compartments containing the reagent components used, but is not limited thereto.
[0062] The kit of the present invention may include not only a preparation capable of measuring the expression level of CNOT11 mRNA or its protein in a patient sample, but also one or more compositions, solutions, or devices suitable for analyzing the expression level. For example, the kit may include, but is not limited to, a substrate, a suitable buffer solution, a secondary antibody labeled with a detection label, and a chromogenic substrate for the immunological detection of an antibody.
[0063] As a specific example, the above kit may be a kit characterized by including essential elements necessary to perform ELISA in order to implement various ELISA methods, such as ELISA kits and sandwich ELISAs. Such an ELISA kit includes antibodies specific to the proteins. The antibody is an antibody with high specificity and affinity for CNOT11 and little cross-reactivity with other proteins, and may be a monoclonal antibody, a polyclonal antibody, or a recombinant antibody. Additionally, the ELISA kit may include antibodies specific to a control protein. Furthermore, the ELISA kit may include, but is not limited to, reagents capable of detecting the bound antibody, such as labeled secondary antibodies, chromophores, enzymes and their substrates, or other substances capable of binding to the antibody.
[0064] In addition, the above kit may be a kit for implementing Western blot, immunoprecipitation analysis, complement fixation analysis, flow cytometry, or protein chips, and may additionally include additional components suitable for each analysis method. Through these analysis methods, colorectal cancer can be diagnosed by comparing the amount of antigen-antibody complex formation.
[0066] The present invention relates to a method for providing information for the diagnosis of colorectal cancer.
[0067] The method of the present invention includes the step of measuring the expression level of CNOT11 mRNA or the protein thereof in a sample separated from a diagnostic subject.
[0068] The above measurement may be performed by treating the sample with a substance that specifically binds to CNOT11 mRNA or the protein.
[0069] The substance that specifically binds to the above CNOT11 mRNA or its protein may be within the range previously exemplified.
[0070] The above samples and diagnostic targets are as described above.
[0071] As a method for measuring the level of CNOT11 mRNA or the protein expression level, a method of measuring the concentration of mRNA, which is a transcript of the gene encoding CNOT11, in a sample or the concentration of CNOT11 protein in a sample may be chosen, but is not limited thereto, and may be performed by choosing a method commonly used in the technical field of the present invention.
[0072] Methods for measuring the concentration of the mRNA in a sample include, but are not limited to, reverse transcriptase polymerase chain reaction (RT-PCR), competitive reverse transcriptase polymerase chain reaction (Competitive RT-PCR), real-time reverse transcriptase polymerase chain reaction (Real-time RT-PCR), RNase protection assay (RPA), Northern blotting, and DNA chips.
[0073] As a method for measuring the concentration of the above protein in a sample, the amount of protein can be determined using an antibody that specifically binds to the above protein. Analytical methods for this purpose include, but are not limited to, immunoassay, sandwich assay, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), radioimmunodiffusion, Ouchterlony immunodiffusion, rocket immunoelectrophoresis, immunohistochemistry, immunoprecipitation assay, complement fixation assay, fluorescence-activated cell sorting (FACS), Western blotting, flow cytometry, enzyme substrate chromogenesis, antigen-antibody agglutination, and protein chip.
[0074] The method of the present invention may further include the step of comparing the expression level with the expression level of a control group.
[0075] By comparing the expression level of CNOT11 mRNA or its protein in a sample from a patient suspected of having colorectal cancer with the expression level of a normal control group, if the CNOT11 expression level of the patient suspected of having colorectal cancer is higher than that of the normal control group, it can be determined that the patient suspected of having colorectal cancer has a high probability of developing colorectal cancer. In addition, if the expression level of the CNOT11 mRNA or its protein is measured to be statistically not significantly different (e.g., p<0.05) or lower compared to the expression level of the normal control group, it can provide information that the patient suspected of having colorectal cancer has a low probability of developing colorectal cancer.
[0076] In addition, by comparing the expression levels of CNOT11 mRNA or its protein in samples from two patients suspected of having colorectal cancer, it can be determined that the patient with the higher expression level has a higher likelihood of developing colorectal cancer than the patient with the lower expression level.
[0077] In addition, by comparing the expression level of CNOT11 mRNA or its protein in the sample of a patient suspected of having colorectal cancer with the expression level of a patient with colorectal cancer, if there is no statistically significant difference between the expression level of the patient suspected of having colorectal cancer and the expression level of a patient with colorectal cancer (P<0.05), it can be determined that there is a high probability of developing colorectal cancer.
[0079] The present invention relates to a pharmaceutical composition for the prevention or treatment of colorectal cancer.
[0080] The composition of the present invention includes a CNOT11 inhibitor.
[0081] The above CNOT11 inhibitor is a substance that inhibits the expression or activity of the CNOT11 gene or protein. For example, it may be a nucleic acid, antibody, aptamer, peptide, protein, compound, or natural product, and is not particularly limited as long as it inhibits the expression or activity of the CNOT11 gene or protein.
[0082] More specific examples may include nucleic acids such as antisense nucleotides that bind complementarily to CNOT11 mRNA, small interfering RNA (siRNA), short hairpin RNA (shRNA), microRNA, or recombinant RNA, and may be antibodies, aptamers, peptides, proteins, compounds, or natural products that specifically bind to CNOT11.
[0083] The above-mentioned prevention or treatment of colorectal cancer may be achieved by inhibiting c-Myc activity or inducing ferroptosis.
[0084] The composition of the present invention contains a CNOT11 inhibitor, thereby inhibiting the activity of the oncogene c-Myc and reducing the expression of ferroptosis-related genes such as GPX4, and inducing cancer cell death through ferroptosis, thus having an excellent effect in preventing or treating colorectal cancer.
[0085] The pharmaceutical composition of the present invention further comprises a pharmaceutically acceptable carrier that is commonly used in formulations, including but not limited to lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
[0086] The pharmaceutical composition of the present invention may additionally include, in addition to the above components, lubricants, humectants, sweeteners, flavorings, emulsifiers, suspending agents, preservatives, etc. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995). Suitable dosage of the pharmaceutical composition of the present invention varies depending on factors such as the method of formulation, mode of administration, age, body weight, sex, severity of disease symptoms, food, time of administration, route of administration, excretion rate, and response sensitivity, and a physician of ordinary skill can easily determine and prescribe a dosage effective for the intended treatment. Meanwhile, the dosage of the pharmaceutical composition of the present invention is not limited thereto and may be 0.01 to 2000 mg / kg (body weight) per day.
[0087] The pharmaceutical composition of the present invention may be administered orally or parenterally. When administered parenterally, it may be administered via intravenous infusion, subcutaneous infusion, intramuscular infusion, intraperitoneal infusion, transdermal administration, etc. It is preferable that the route of administration of the pharmaceutical composition of the present invention be determined according to the type of disease to which it is applied.
[0088] The pharmaceutical composition of the present invention may be prepared in a unit dose form or contained in a multi-dose container by formulation using a pharmaceutically acceptable carrier and / or excipient, according to a method that can be easily carried out by a person skilled in the art to which the invention belongs. In this case, the formulation may be in the form of a solution, suspension, or emulsion in an oil or aqueous medium, or in the form of an extract, powder, granule, tablet, or capsule, and may additionally include a dispersant or a stabilizer.
[0090] The present invention relates to a health food for the prevention or improvement of colorectal cancer.
[0091] The composition of the present invention includes a CNOT11 inhibitor.
[0092] The CNOT11 inhibitor included in the health functional food of the present invention, its mechanism of action, and its effects are as described above.
[0093] The health functional food of the present invention can be manufactured and processed in the form of tablets, capsules, powder, granules, liquid, pills, etc. for the purpose of preventing or improving colorectal cancer.
[0094] The term "health functional food" of the present invention refers to a food manufactured and processed using raw materials or ingredients that have functional properties useful to the human body, and means consuming it for the purpose of obtaining useful effects for health purposes, such as regulating nutrients or physiological actions regarding the structure and function of the human body.
[0095] The health functional food of the present invention may include conventional food additives, and unless otherwise specified, suitability as a food additive is determined in accordance with the specifications and standards for the relevant item, based on the general provisions and general test methods of the food additive code approved by the Korea Food and Drug Administration.
[0096] The items listed in the above food additives code include, for example, chemically synthesized products such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamon acid; natural additives such as cinnamon dye, crystalline cellulose, sorghum dye, and guar gum; and mixed preparations such as L-sodium glutamate preparations, alkaline noodle additives, preservative preparations, and tar dye preparations, but are not limited thereto.
[0097] For example, a health functional food in tablet form may be produced by granulating a mixture of the inhibitor with excipients, binders, disintegrants, and other additives using a conventional method, and then adding a lubricant or the like and compression molding, or by directly compression molding the mixture. Additionally, the health functional food in tablet form may contain a binder or the like as needed.
[0098] Among the capsule-type health functional foods, hard capsules can be manufactured by filling a conventional hard capsule with a mixture in which the inhibitor is mixed with additives such as excipients, and soft capsules can be manufactured by filling a capsule base such as gelatin with a mixture in which the inhibitor is mixed with additives such as excipients. The soft capsules may contain plasticizers such as glycerin or sorbitol, coloring agents, preservatives, etc., as needed.
[0099] Health functional foods in the form of pills may be prepared by molding a mixture of the above-mentioned inhibitor, excipients, binders, disintegrants, etc., using a previously known method, and may be coated with sucrose or other coating agents as needed, or the surface may be coated with a substance such as starch or talc.
[0100] A health functional food in granular form can be manufactured into a granular form by a previously known method using a mixture of the above-mentioned inhibitor, excipients, binders, disintegrants, etc., and may contain flavoring agents, stimulants, etc. as needed.
[0101] The above health functional foods may be beverages, meat, chocolate, food products, confectionery, pizza, ramen, other noodles, chewing gum, candy, ice cream, alcoholic beverages, vitamin complexes, and health supplements.
[0102] The above-mentioned health functional food may be taken orally for use as a nutritional supplement, and the form of application is not particularly limited.
[0104] The present invention relates to a screening method for colorectal cancer treatments.
[0105] The method of the present invention comprises the steps of: treating a biological sample expressing CNOT11 mRNA or its protein with a candidate substance; measuring the expression level of CNOT11 mRNA or its protein in the sample treated with the candidate substance; and selecting a candidate substance whose expression level is reduced compared to a control group not treated with the candidate substance.
[0106] The method of treating a candidate substance on a biological sample is not particularly limited and may involve treating a candidate substance on tissue, cell, blood, serum, plasma, saliva, or urine isolated from an individual.
[0107] The expression level of CNOT11 mRNA or its protein can be measured by the method described above.
[0108] The present invention has confirmed that colorectal cancer is treated when the expression level of the CNOT11 gene in colorectal cancer cells increases and decreases. If a candidate substance is treated to a biological sample expressing CNOT11 mRNA or protein and the expression level of CNOT11 mRNA or protein in the sample decreases, the candidate substance can be selected as a colorectal cancer treatment.
[0109] This can be done by measuring the expression level of CNOT11 mRNA or protein in a sample before treating a biological sample with a candidate substance and comparing the expression level after treatment, or by treating multiple samples with the candidate substance and comparing the expression level with a control group.
[0110] The above candidate substance refers to an unknown substance used in screening to determine whether it affects the expression level of CNOT11 mRNA or protein. The above candidate substance includes, for example, chemical substances, nucleotides, antisense RNA, siRNA (small interference RNA), and natural product extracts, but is not limited thereto.
[0112] Hereinafter, in order to specifically explain the present invention, it will be described in detail with reference to examples.
[0114] 1. Comparison of CNOT11 expression levels in colorectal cancer cell lines and colon cells
[0115] The expression levels of the CNOT11 gene were compared in normal colon cells and colon cancer cell lines. Each cell line was collected, proteins were extracted using NP-40 lysis buffer, and the expression of CNOT11 and β was confirmed by western blotting. As shown in Figure 1, it was found that CNOT11 expression was specifically higher in most colon cancer cells compared to normal colon cells.
[0117] 2. Confirmation of the growth inhibitory effect of CNOT11 siRNA introduction into colorectal cancer cell lines
[0118] Colorectal cancer cell line HCT116 p53+ / + 1 x 10⁶ of each cell line in a 96-well plate 4 Cultured at cells / ml, and INTERFERIN with CNOT11 siRNA at a concentration of 80 nM ®It was introduced using (Polyplus, France). After 72 hours of introduction, the absorbance was measured at a wavelength of 450 nm using a CCK8 assay. As a result, as shown in Figure 2A, it was confirmed that the survival of colorectal cancer decreased when CNOT11 gene expression was suppressed by introducing CNOT11 siRNA into colorectal cancer cells.
[0119] Colorectal cancer cell line HCT116 p53+ / + 7x10 of each cell line in a 6-well plate 4 Cultured at cells / ml, and INTERFERIN with CNOT11 siRNA at a concentration of 80 nM ® 1X10 72 hours after introduction using (Polyplus, France) 3 After culturing at a rate of cells / ml, the difference in colonies was checked. As a result, as shown in Figure 2B, it was confirmed that the cell proliferation rate of the group treated with CNOT11 siRNA was lower than that of the control group.
[0121] 3. HCT116 with CNOT11 siRNA introduced p53+ / + Confirmation of changes in the activity of the oncogene c-Myc in colorectal cancer cell lines
[0122] Colorectal cancer cell lines in a 6-well plate (7x10 4 After cell culture at cells / ml, CNOT11 siRNA at a concentration of 80 nM INTERFERIN ® It was introduced using Polyplus (Polyplus, France). After 72 hours, cells were collected and proteins were extracted, and the protein expression of c-Myc, CNOT11, and β was confirmed by western blotting. As a result, as shown in Figure 3A, it was confirmed that the decrease in protein expression of the oncogenic gene c-Myc proceeded in a concentration-dependent manner with siRNA.
[0123] Colorectal cancer cell lines in a 6-well plate (7x10 4After cell culture at cells / ml, CNOT11 siRNA at a concentration of 80 nM INTERFERIN ® Introduced using Polyplus (Polyplus, France). Cells were collected at 0, 24, 48, and 72 hours after introduction, and proteins were extracted. Protein expression of c-Myc, CNOT11, and β was confirmed by western blotting. As shown in Figure 3B, it was confirmed that the protein expression of the oncogenic gene c-Myc decreased in a time-dependent manner upon treatment with CNOT11 siRNA.
[0125] 4. HCT116 with CNOT11 siRNA introduced p53+ / + Confirmation of c-Myc expression in colorectal cancer cell lines
[0126] 3x10 of each cell line in a 4-well plate 4 After cell culture at cells / ml, CNOT11 siRNA at a concentration of 80 nM INTERFERIN ® It was introduced using Polyplus (Polyplus, France). After 72 hours, c-Myc was treated with the primary antibody, and after 24 hours, Alexa Fluor 488 was treated as the secondary antibody. After DAPI staining, fluorescence microscopy was performed at 10x magnification. The expression of c-Myc was compared between the siRNA-treated group and the untreated control group. As a result, as shown in Figure 4, the location of the nucleus and the expression of c-Myc in the cells were confirmed.
[0128] 5. HCT116 with siRNA CNOT11 introduced p53+ / + Confirmation of ferroptosis induction in colorectal cancer cell lines
[0129] Cell line in a 6-well plate, 7x10 4 After cell culture at cells / ml, CNOT11 siRNA at a concentration of 80 nM INTERFERIN ®Cells were introduced using Polyplus (Polyplus, France). After 72 hours, cells were collected and proteins were extracted, and the protein expression of GPX4, xCT / SLC7A11, keap1, CNOT11, and β was confirmed by western blotting. As shown in Figure 5A, it was confirmed that the protein expression of factors involved in the induction of ferroptosis decreased, and that the induction of ferroptosis proceeded in a concentration-dependent manner with siRNA.
[0130] Interferin with CNOT11 siRNA at a concentration of 80 nM in cell lines ® It was introduced using (Polyplus, France) and treated with 10 μM of ferrostatin-1. As shown in Figure 5 B, fluorescence microscopy observation after DCFDA treatment revealed that ROS was generated in the group treated with siRNA compared to the control group, and that the group treated with ferrostatin-1 showed reduced ROS generation compared to the group treated with siRNA.
[0132] Synthesizing the above results, it was found that when CNOT11 siRNA is introduced into colon cancer cells and the CNOT11 gene is inhibited, the growth of colon cancer cells is suppressed, the expression of the oncogene c-Myc is regulated, and ferroptosis is induced.
Claims
Claim 1 A composition for diagnosing colorectal cancer comprising a substance that specifically binds to CNOT11 (CCR4-NOT Transcription Complex Subunit 11) mRNA or the protein thereof. Claim 2 A composition according to claim 1, wherein the material is at least one selected from the group consisting of antibodies, aptamers, DNA, RNA, proteins, and polypeptides. Claim 3 A colorectal cancer diagnostic kit comprising the composition of claim 1. Claim 4 A method for providing information for the diagnosis of colorectal cancer, comprising the step of measuring the expression level of CNOT11 mRNA or the protein thereof in a sample isolated from a diagnostic subject. Claim 5 A method according to claim 4, further comprising the step of determining that if the expression level is higher than the expression level of the control group, the diagnostic subject has a higher probability of developing colorectal cancer compared to the control group. Claim 6 A method according to claim 4, wherein the sample is selected from the group consisting of tissue, cell, blood, serum, plasma, saliva, or urine. Claim 7 A pharmaceutical composition for the prevention and treatment of colorectal cancer comprising a CNOT11 inhibitor, wherein the prevention and treatment are achieved by inducing ferroptosis. Claim 8 A pharmaceutical composition according to claim 7, wherein the CNOT11 inhibitor is a nucleic acid, antibody, aptamer, peptide, protein, compound, or natural product. Claim 9 A pharmaceutical composition according to claim 7, wherein the prevention and treatment are achieved by inhibiting c-Myc activity. Claim 10 A health functional food for the prevention and improvement of colorectal cancer comprising a CNOT11 inhibitor, wherein the prevention and improvement are achieved by the induction of ferroptosis. Claim 11 A method for screening a colorectal cancer treatment, comprising: a step of treating a biological sample expressing CNOT11 mRNA or its protein with a candidate substance; a step of measuring the expression level of CNOT11 mRNA or its protein in the sample treated with the candidate substance; a step of selecting a candidate substance whose expression level is reduced compared to a control group not treated with the candidate substance; and a step of further confirming that the selected candidate substance induces ferroptosis. Claim 12 A method according to claim 11, wherein the biological sample is selected from the group consisting of tissue, cell, blood, serum, plasma, saliva, or urine.
Citation Information
Patent Citations
Biomarker for colon cancer diagnosis and pharmaceutical composition for preventing or treating colon cancer
KR1020220145688A
